size-exclusion HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
=== Biosynthesis === In terms of biosynthesis, oxycodone has been found naturally in nectar extracts from the orchid family Epipactis helleborine; together along with other chemicals: 3-{2-{3-{3-benzyloxypropyl}-3-indol and 7,8-didehydro-4,5-epoxy-3,6-d-morphinan. Thodey et al., 2014 introduce a microbial compound manufacturing system for compounds including oxycodone. The Thodey platform produces both natural and semisynthetic opioids including this one. This system uses Saccharomyces cerevisiae with transgenes from Papaver somniferum (the opium poppy) and Pseudomonas putida to turn a thebaine input into other opiates and opioids.
== History == The US Food and Drug Administration (FDA) approved trastuzumab deruxtecan based on the results of one clinical trial enrolling 184 female participants with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. These participants were heavily pretreated in the metastatic setting, receiving between two and 17 therapies prior to receiving trastuzumab deruxtecan. Participants in the clinical trial received trastuzumab deruxtecan every three weeks and tumor imaging was obtained every six weeks. The overall response rate was 60.3%, which reflects the percentage of participants who had a certain amount of tumor shrinkage with a median duration of response of 14.8 months. Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in participants with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy. A total of 188 participants were randomized (2:1) to receive trastuzumab deruxtecan 6.4 mg/kg intravenously every three weeks or physician's choice of either irinotecan or paclitaxel monotherapy.
== Identification in biological samples == A gas chromatography–mass spectrometry (GC–MS) method for the determination of fenethylline and related substances in plasma, urine, and hair has been developed, suggesting that hair testing can be useful for determining a drug history of fenethylline, and discrimination between fenethylline and its precursor, amphetamine.
== C == Calymmatobacterium granulomatis Campylobacter Campylobacter coli Campylobacter fetus Campylobacter jejuni Capnocytophaga canimorsus Cardiobacterium hominis Chlamydia Chlamydia trachomatis Chlamydophila Chlamydophila pneumoniae (formerly Chlamydia pneumoniae) Chlamydophila psittaci (formerly Chlamydia psittaci) Citrobacter Citrobacter freundii Citrobacter koseri Clostridioides difficile (also known as C. diff) Clostridium Clostridium botulinum Clostridium novyi Clostridium perfringens (formerly Clostridium welchii) Clostridium septicum Clostridium tetani Corynebacterium Corynebacterium diphtheriae (formerly Mycobacterium diphtheriae) Corynebacterium urealyticum Coxiella burnetii Cutibacterium acnes (formerly Propionibacterium acnes)
Sources: en.wikipedia.org
=== Based on absorption === Drugs that change intestinal motility may impact the level of other drugs taken. For example, prokinetic agents increase the intestinal motility, which may cause drugs to go through the digestive system too fast, reducing absorption. The pharmacological modification of pH can affect other compounds. Drugs can be present in ionized or non-ionized forms depending on pKa, and neutral compounds are usually better absorbed by membranes. Medication like antacids can increase pH and inhibit the absorption of other drugs such as zalcitabine, tipranavir and amprenavir. The opposite is more common, with, for example, the antacid cimetidine stimulating the absorption of didanosine. Some resources describe that a gap of two to four hours between taking the two drugs is needed to avoid the interaction. Factors such as food with high-fat content may also alter the solubility of drugs and impact its absorption. This is the case for oral anticoagulants and avocado. The formation of non-absorbable complexes may occur also via chelation, when cations can make certain drugs harder to absorb, for example between tetracycline or the fluoroquinolones and dairy products, due to the presence of calcium ions. . Other drugs bind to proteins. Some drugs such as sucralfate bind to proteins, especially if they have a high bioavailability. For this reason its administration is contraindicated in enteral feeding. Some drugs also alter absorption by acting on the P-glycoprotein of the enterocytes.
Murchison contains common amino acids such as glycine, alanine, and glutamic acid as well as unusual ones such as isovaline and pseudoleucine. A complex mixture of alkanes was isolated as well, similar to that found in the Miller–Urey experiment. Serine and threonine, usually considered to be earthly contaminants, were conspicuously absent in the samples. A specific family of amino acids called diamino acids was identified in the Murchison meteorite as well. The initial report in 1970 stated that the amino acids were racemic and therefore formed in an abiotic manner, because amino acids of terrestrial proteins are all of the L-configuration of chirality. Later, in 1982, it was reported that the amino acid alanine had an excess of the L-configuration, but this is a protein amino acid which led several scientists to suspect terrestrial contamination according to the argument that it would be "unusual for an abiotic stereoselective decomposition or synthesis of amino acids to occur with protein amino acids but not with non-protein amino acids". But in 1997, L-excesses were also reported for several non-protein amino acids, suggesting an extraterrestrial source for molecular asymmetry in the Solar System. Some amino acids were found to be racemic (equal quantities of right-handed and left-handed). Around the same time, an enrichment in the isotope 15N was reported, however this result and the non-racemicity of alanine (but not of the others) were explained as possibly due to analysis error.
Intra-articular steroid injections often help with treatment in oligoarticular JIA. Conventional synthetic DMARDs, such as methotrexate are a first-line therapy, and biologic DMARDs such as TNF-α inhibitors may be added on for refractory cases. Rheumatoid factor-negative polyarticular JIA (15-20% of all JIA cases) can be treated with synthetic conventional DMARDs (such as methotrexate), with biologic DMARDs (such as TNF inhibitors) being a second-line add-on treatment option. Rheumatoid factor-positive JIA (5% of JIA cases, and also being rare in children younger than 9-years old) is associated with a poor prognosis, and early treatment is required to prevent significant joint destruction and disability. It is very similar pathologically to adult rheumatoid arthritis. Synthetic conventional DMARDs or biologic DMARDs are standard therapy for this type of JIA. Enthesitis-related arthritis is a type of JIA characterized by enthesitis; inflammation of the area where tendons and ligaments attach to bone. NSAIDs are commonly used for symptomatic relief, with the anti-inflammatories sulfasalazine and TNF inhibitors also being used. Biologic DMARDs such as TNF-α inhibitors are used for sacroilitis (inflammation of the sacroiliac joint). IL-17 inhibitors are used for refractory disease. 40-60% of children with enthesitis-related variant of JIA have involvement of the axial skeleton, including sacroiliitis, spondyloarthritis, and ankylosing spondylitis (inflammation of the spine).
== Symptoms and signs == In the event more ATP is needed from the affected pathway, the lack of it becomes an issue and symptoms develop. People with a metabolic myopathy often experience symptoms such as:
Most white Rhodesians felt that they were due independence following four decades of self-government, and that the British government was betraying them by withholding it. A stalemate developed between the British and Rhodesian prime ministers, Harold Wilson and Ian Smith respectively, between 1964 and 1965. The dispute largely surrounded the British condition that the terms for independence had to be acceptable "to the people of the country as a whole"; Smith contended that this was met, while the UK and African Nationalist Rhodesian leaders held that it was not. After Wilson proposed in late October 1965 that the UK might safeguard future black representation in the Rhodesian parliament by withdrawing some of the colonial government's devolved powers, then presented terms for an investigatory Royal Commission that the Rhodesians found unacceptable, Smith and his Cabinet declared independence. Calling this treasonous, the British colonial governor, Sir Humphrey Gibbs, formally dismissed Smith and his government, but they ignored him and appointed an "Officer Administering the Government" to take his place. While no country recognised the UDI, the Rhodesian High Court deemed the post-UDI government legal and de jure in 1968. The Smith administration initially professed continued loyalty to Queen Elizabeth II, but abandoned this in 1970 when it declared a republic in an unsuccessful attempt to win foreign recognition.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.